North America Skin Cancer Dermatology Market: Current Analysis and Forecast (2022-2028)

Skin cancer is a type of cancer that originates in the skin. It occurs when abnormal cells in the skin start growing uncontrollably and form a mass or tumor. Skin cancer is usually caused by exposure to ultraviolet (UV) radiation from the sun or tanning beds. Skin cancer is typically diagnosed by a dermatologist, who can perform a skin biopsy to confirm the diagnosis. In addition, early detection and treatment of skin cancer can increase the chances of a successful outcome.

The North America Skin Cancer Dermatology Market is expected to grow at a strong CAGR of 6% during the forecast period owing to the growing awareness of the importance of skin health. Moreover, an increasing prevalence of skin-related diseases, including skin cancer around the country is also helping the market grow at a strong growth rate. For instance, The American Cancer Society's evaluations for melanoma in the United States in 2023 are around 5,420 men and 2,570 women are anticipated to die of melanoma.

Based on test type, the North America skin cancer dermatology market is segmented into skin biopsy and diagnostic imaging. Diagnostic imaging is expected to grow with a significant CAGR during the forecast period. This is mainly due to the launches of improved non-invasive techniques, such as high-frequency ultrasound, magnetic resonance imaging, and laser scanning confocal microscopy. For instance, in September 2022, Guerbet announced the approval of Elucirem Injection for use in contrast-enhanced ( magnetic resonance imaging) MRI by the U.S. Food and Drug Administration (FDA). However, the high adoption of these techniques increases the demand for diagnostic imaging.

By facility type, the North America skin cancer dermatology market is segmented into hospital outpatient departments, stand-alone practices, and multispecialty clinics. As per our analysis, the stand-alone practices segment is expected to grow with a significant CAGR during the forecast period. This is mainly due to the presence of highly qualified dermatologists with a variety of diagnostic and treatment facilities in the region.

On the basis of age group, the market is segmented into 0-19, 20-39, 40-64, 65-84, and 85 and above. According to our observation, the 65-84 age group held a major share of the North America skin cancer dermatology market in 2021 owing to the rising prevalence of skin cancer in the geriatric population. The Centers for Disease Control and Prevention estimated 7,085 cases of new melanomas of skin in the age group of 80-84 in the United States, in 2019.

For a better understanding of the market adoption of the North America skin cancer dermatology industry, the market is analyzed based on its country presence in the countries such as the U.S., Canada, and the Rest of North America. The U.S. dominated the North America skin cancer dermatology market in 2021 due to the increased demand for skin cancer dermatology services in the U.S., with dermatologists being the primary healthcare providers for diagnosing and treating skin cancer. The U.S. healthcare system has responded to this demand by increasing the number of dermatology clinics and facilities across the country. Currently, melanoma disorder is 20 times more common in White people than in Black people as per the American Cancer Society.

Some of the major players operating in the market include: Speclipse, Inc.; Agilent Technologies, Inc.; MetaOptima Technology Inc.; FotoFinder Systems, Inc; Canfield Scientific, Inc.; SkinIO, Inc.; Firefly Health, Inc.; DermLite; Eli Lilly and Company; Bristol-Myers Squibb Company.